



ASX ANNOUNCEMENT

CELLMID REPAID REMAINING \$1 MILLION OF R&D LOAN

SYDNEY, Thursday, 1 November 2018: Cellmid Limited (ASX: CDY) advises that it has repaid the remaining \$1 million of the \$2 million R&D loan facility provided to it by Platinum Road in February 2017.

The R&D loan facility was originally negotiated for two years, and was due to be repaid at the end of February 2019, with a simple interest of 12% per annum payable in arrears. The loan conditions include the right for Cellmid to repay the full amount during the last 12 months of the loan.

In the notes to the Appendix 4C released on 15 October 2018 Cellmid advised that it had repaid \$1 million of the \$2 million loan facility following completion of the private placement and share purchase plan. This repayment saved Cellmid \$50,000 in interest. By repaying the remaining \$1 million of the loan early, Cellmid will save a further \$40,000; a total of \$90,000 in interest.

With the recent \$10.03 million fund raising, \$9 million in a private placement, a further \$1 million via a share purchase plan, and the R&D tax credit received of \$808K, Cellmid has a strong balance sheet with the ability to manage its cash reserves to maximise the growth potential of the business and continue on the path of improved financial performance.

END

Company Maria Halasz, CEO Cellmid T +612 9221 6830	Investor Relations & Media Kyahn Williamson WE Buchan T + 61 401018828 kwilliamson@we-buchan.com
--	--



Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, Japan, USA and China. For further information, please see www.cellmid.com.au and www.myevolis.com.au.

Advangen Limited and hair growth products

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. With the Fillerina® distribution agreement Advangen has its first skincare range.

Forward looking statements

This announcement has a number of forward looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.